15
Aug
2026
The Other Side of Bayes: Rethinking False Positives in Health Screening
Imagine screening 10,000 apparently healthy people for a disease that affects one person in a thousand. Let’s further assume the test is fairly good: 99% sensitive and 99% specific. (In case it’s been a while, this means the test detects 99% of true cases and correctly exonerates 99% of people without disease.) Ten of those 10,000 people will actually have... Read More
14
Aug
2026
AI in Drug R&D: At Last, the End of the Beginning
With the emergence of AI as an increasingly dominant force in industry (and society), much of the early discussion around AI in biopharma has tended to treat it largely as an abstraction. Advocates and investors insist AI is a transformative superhuman technology poised to domesticate R&D, while cynics, including many grizzled drug hunters, tend to assume it’s just the latest... Read More
13
Aug
2026
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Aug
2026
Genetic Medicines For Kidney Diseases: Jason Coloma on The Long Run
Jason Coloma is today’s guest on The Long Run. Jason is the CEO of South San Francisco-based Maze Therapeutics. The company is developing small molecule drugs to halt or potentially reverse kidney diseases. The drug discovery work at Maze is grounded in human genetics, looking at large pools of data to see how variants of one kind or another can... Read More
6
Aug
2026
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2026
LifeMine, In Verdine’s Big Year, Raises $263M For Safer Drug for Organ Transplants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jul
2026
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jul
2026
Inhalable Medicines for Severe Lung Diseases: Lyn Baranowski on The Long Run
Lyn Baranowski is today’s guest on The Long Run. Lyn is the CEO of Boston-based Avalyn Pharma. The company is developing inhalable drugs for rare, severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases. Avalyn has taken a couple of small molecules that are given orally, and remade them into inhalable drugs so they can be more... Read More
23
Jul
2026
Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2026
Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Jul
2026
A Schizophrenia Drug Patients Can Stick With: Heather Turner on The Long Run
Heather Turner is today’s guest on The Long Run. Heather is the CEO of New York-based LB Pharmaceuticals. It’s developing treatments for serious mental health disorders such as schizophrenia, depression, and bipolar disorder. The company is running late-stage clinical trials for its lead drug candidate, LB102. It’s a methylated derivative of amisulpride, a benzamide antipsychotic. It’s approved in more than... Read More
11
Jul
2026
Useful Fictions or Distorting Frames? How Models Shape Drug R&D
We rely on models — deliberate simplifications — to navigate, make sense of, and engage productively with an ever-more complicated world. Patients understand their illnesses through what Dr. Arthur Kleinman called “explanatory models.” Physicians use models such as the pathophysiologic model or the biopsychosocial model to integrate their patients’ symptoms and fashion treatments. Biopharma R&D would be impossible without models... Read More
30
Jun
2026
Precision Cancer Drugs and Combos: Troy Wilson on The Long Run
Troy Wilson is today’s guest on The Long Run. Troy is the co-founder and CEO of San Diego-based Kura Oncology. The company, founded in 2014, has gone all the way through R&D to develop its own novel cancer drug. It’s called ziftomenib (brand name Komzifti). It’s an oral pill that inhibits a target called menin. Ziftomenib was approved by the... Read More
29
Jun
2026
The Rise, Fall, and Rise (and Fall…?) of Cell and Gene Therapy
More than $14 billion in announced acquisition value has flowed into in vivo cell therapy companies over the last 18 months. Lilly acquired Kelonia, AbbVie bought Capstan, BMS acquired Orbital, and AstraZeneca bought EsoBiotec, to name a few. These acquisitions demonstrate that we’re getting closer to the day when single injections that reprogram cells can fight disease without complex shipping logistics,... Read More
25
Jun
2026
AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2026
Ollin Advances with $330M to Challenge Roche in DME & Wet AMD
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jun
2026
Kardigan Continues IPO Trend & FDA Reconsiders UniQure and Moderna
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jun
2026
Small Molecules To Correct Disease: Sri Kosuri on The Long Run
Sri Kosuri is today’s guest on The Long Run. Sri is the co-founder and CEO of Emeryville, California-based Octant Bio. The company is developing oral small molecule drugs that are designed to correct protein misfolding and mistrafficking. Quite a few rare diseases, cancers, and metabolic disorders are thought to be amenable to this strategy. Octant’s work starts with a platform... Read More
11
Jun
2026
Parabilis IPO Pops, J&J Buys More Degraders, & GSK’s Precision Oncology Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2026
City Therapeutics Pockets $99.5M, Advances RNAi Candidates to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.